secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0001370053-24-000039
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio Q2 net loss $46.7M; cash $393.5M; ANB032 Phase 2b enrollment complete, data Dec 2024
--------------------------------------------------------------------------------

- Net loss of $46.7M ($1.71 per share) for Q2 2024, vs $39.8M loss ($1.50) in Q2 2023.
- Cash & investments $393.5M as of June 30, 2024; runway reiterated through year-end 2026.
- Completed enrollment (~200 patients) for ANB032 Phase 2b in atopic dermatitis; top-line data expected Dec 2024.
- Rosnilimab Phase 2b RA top-line data accelerated to Q1 2025; Phase 2 UC data now expected Q1 2026.
- IND for ANB033 (anti-CD122) accepted by FDA; Phase 1 trial initiation anticipated in Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005324000039/0001370053-24-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005324000039/anab-20240805.htm
  HTML page:      https://secwatch.observer/filing/0001370053-24-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer